Silo pharma and strategic partner zylo therapeutics begin development process for novel ketamine loaded z-pods

Englewood cliffs nj, nov. 18, 2021 (globe newswire) -- silo pharma, inc. (otcqb: silo) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner zylo therapeutics received its first ketamine shipment and initiated loading ketamine into their z-pod® transdermal technology.
SILO Ratings Summary
SILO Quant Ranking